Kamada (NASDAQ:KMDA) Issues Earnings Results, Misses Estimates By $0.03 EPS

Kamada (NASDAQ:KMDA) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03), FiscalAI reports. The company had revenue of $44.68 million for the quarter, compared to analyst estimates of $145.07 million. Kamada had a return on equity of 7.89% and a net margin of 11.70%.

Here are the key takeaways from Kamada’s conference call:

• Kamada affirmed 2026 guidance of $200–$205 million in revenues and $50–$53 million of adjusted EBITDA, implying ~13% and ~23% midpoint growth driven solely by organic initiatives.
• Strong 2025 financials — revenue of $180.5 million (+12%), adjusted EBITDA of $42 million (+23%), $25.5 million cash from operations, and a declared dividend of $0.25 per share (~$14.4 million).
• Commercial momentum in lead products — KedRAB sales rose to ~$54 million in 2025 with a firm $90 million minimum commitment for 2026–2027 and supply through 2031; Varizig and GLASSIA also contributed growth, including a WHO tender for Varizig in Latin America.
• Cytogam sales declined in 2025, which management attributes to greater uptake and access of antivirals; the company has launched a post‑marketing research program (including the SHIELD trial) to try to recover usage.
• Plasma collection ramp underway — centers are ~30–40% ramped (Houston FDA‑approved; San Antonio expected H1‑2026), targeting full capacity by end‑2027, with specialty‑plasma margin benefits expected to start in 2027 and beyond.

Kamada Stock Performance

NASDAQ:KMDA opened at $8.55 on Thursday. Kamada has a fifty-two week low of $5.54 and a fifty-two week high of $9.35. The company has a 50 day moving average price of $8.38 and a 200 day moving average price of $7.44. The stock has a market capitalization of $491.71 million, a P/E ratio of 23.75, a PEG ratio of 0.75 and a beta of 0.94.

Kamada Announces Dividend

The business also recently disclosed an annual dividend, which will be paid on Monday, April 6th. Investors of record on Monday, March 23rd will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Monday, March 23rd. This represents a dividend yield of 292.0%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on KMDA shares. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Stifel Nicolaus set a $11.00 price target on shares of Kamada in a report on Wednesday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. Benchmark reiterated a “buy” rating on shares of Kamada in a research report on Thursday, January 8th. Finally, HC Wainwright raised their target price on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Kamada in the first quarter valued at $206,000. NewEdge Advisors LLC lifted its stake in Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 28,165 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in Kamada during the 1st quarter valued at about $497,000. Jane Street Group LLC purchased a new position in Kamada during the 1st quarter valued at about $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Kamada in the 2nd quarter valued at about $472,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada News Roundup

Here are the key news stories impacting Kamada this week:

• Positive Sentiment: Kamada declared an annual cash dividend of $0.25 per share (record date Mar 23, payable Apr 6), a direct cash return that can support shareholder demand. Kamada Declares Cash Dividend
• Positive Sentiment: Analyst upgrades from Sidoti: the firm raised Q1/Q3 and FY2026–2027 EPS forecasts (FY2026 now $0.44, FY2027 $0.52), which may support upward revision of expectations. Sidoti estimate updates
• Positive Sentiment: Kamada’s press release describes record full‑year 2025 top‑ and bottom‑line results and reaffirms 2026 guidance, a management message meant to reassure investors about growth trajectory. Record results & guidance
• Neutral Sentiment: Short interest fell ~17.8% in February to ~136.8k shares (0.4% of float), reducing one source of selling pressure but not yet a material squeeze. Short interest update
• Neutral Sentiment: Multiple earnings‑call transcripts and writeups published (Yahoo, Seeking Alpha, SeekingAlpha transcript), useful for detail but primarily informational. Earnings call transcript (Yahoo)
• Negative Sentiment: Q4 report missed expectations: EPS $0.06 vs. $0.09 consensus and reported quarterly revenue $44.68M vs. $145.07M estimate — a substantial miss on revenue that likely drove the negative reaction. Q4 earnings & revenue miss
• Negative Sentiment: TipRanks flagged a new disclosure risk: Kamada’s reliance on externally managed investigator‑initiated trials may pose data integrity and IP risks that could affect longer‑term development value. TipRanks risk note
• Negative Sentiment: Guidance / consensus confusion: one feed shows FY2026 revenue guidance of $200–205M vs. a Street consensus (reported) near $453M — if the lower guidance is accurate or perceived as downbeat, it materially pressures expectations. Investors should confirm official guidance in the company release/FAQ. Guidance note

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.